Ultragenyx Pharmaceutical In (RARE) News Today
RARE fell 1.97% in the 10 minutes after this headline crossed at 08:39:43 ET on Wednesday, Oct 14:
Ultragenyx sold a priority review voucher for $203 million related to a rare pediatric disease.
Price 15.23 two minutes before the headline, 14.93 10 minutes after it.
Latest headline on this page:
Why Ultragenyx Pharmaceutical In (RARE) moved: the full explanation
3 headlines on Ultragenyx Pharmaceutical In appeared in our news feed in the last 7 days with a measured price reaction attached. 2 of them moved the underlying at least 0.35% in the minutes after the headline crossed. The largest measured reaction was +2.21% over 10 minutes on RARE, after the headline at Oct 14, 08:30:00 ET.
Price action when the news broke
08:30:00 ET
What moved RARE — last 7 days
| Time | Headline | 1 min | Reaction |
|---|---|---|---|
| Oct 19, 09:06:43 ET | Ultragenyx Pharmaceutical reaches settlement with Navinta in Dojolvi patent litigation | 0.00% | -0.27% · 10m |
| Oct 14, 08:39:43 ET | Ultragenyx sold a priority review voucher for $203 million related to a rare pediatric disease. | 0.00% | -1.97% · 10m |
| Oct 14, 08:30:00 ET | Ultragenyx Pharmaceutical is selling a priority review voucher for $203 million following FDA approval of its treatment for mucopolysaccharidosis type IIIA. | +2.28% | +2.21% · 10m |
Moves are measured against the price two minutes before each headline crossed, using validated 1-minute bars captured at publish time. A dash means no bar was available for that window. Reaction pending means the measuring window for that headline is still open. Not attributed means the headline does not name the company the move was measured on, so we hold the number back. Times are New York ET. Headlines appear here 1 minute after they cross the live tape.